Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
BRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.21 - $2.55
Previous CloseN/A
Volume34.37K
Average Volume (3M)155.09K
Market Cap
$12.61M
Enterprise Value$8.57M
Total Cash (Recent Filing)$9.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 19, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding7,504,780
10 Day Avg. Volume412,333
30 Day Avg. Volume155,090
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue6.38
Enterprise Value/Gross Profit23.82
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$13.00Price Target Upside673.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
BioRestorative Therapies News
PremiumCompany Announcements
BioRestorative Reports Promising Phase 2 Trial Results
PremiumCompany Announcements
BioRestorative Therapies’ Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
BioRestorative Therapies Reports Q1 2025 Results and UpdatesBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressBRTX-100 received Fast Track designation from the FDA, which could expedite the development process.
Market OpportunityBRTX-100 is the first cell therapy cleared for cervical spinal pain, representing a potential advantage over other MSC products.
Safety ProfileNo serious adverse events or dose-limiting toxicities reported between 24 and 104 weeks at the target dose.
Bears Say
Competitive LandscapeIncreasing regulatory acceptance of MSCs is noted, with other companies making advancements in this space.
Financial PerformanceThe company reported a net loss of ($4.8M) and revenue of $25k.
Options Prices
Currently, No data available
---
Ownership Overview
16.94% Insiders
1.10% Mutual Funds
1.60% Other Institutional Investors
79.96% Public Companies and Individual Investors
BRTX FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was $1.21 and its highest was $2.55 in the past 12 months.
What is BioRestorative Therapies’s market cap?
BioRestorative Therapies’s market cap is $12.61M.
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s upcoming earnings report date is Aug 19, 2025 which is in 63 days.
How were BioRestorative Therapies’s earnings last quarter?
BioRestorative Therapies released its earnings results on May 14, 2025. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.325 by -$0.315.
Is BioRestorative Therapies overvalued?
According to Wall Street analysts BioRestorative Therapies’s price is currently Undervalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate is -0.37.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 7,504,780 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
BioRestorative Therapies reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.325. Following the earnings report the stock price went down -2.339%.
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in BRTX
Company Description
BioRestorative Therapies
BioRestorative Therapies (BRTX) is a biotechnology company focused on the development of innovative therapeutic solutions using cell and tissue therapies. The company operates primarily in the field of regenerative medicine, with a particular emphasis on stem cell-based therapies for the treatment of chronic lumbar disc disease and metabolic disorders. Its core products include BRTX-100, a stem cell-based therapeutic targeting disc/spine disease, and ThermoStem, a program focused on metabolic disorders including obesity and diabetes.
BRTX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
BioRestorative Therapies demonstrated significant progress with their BRTX-100 program, achieving FDA Fast Track designation and clearance for a new clinical trial, positioning the company strongly in the cell-based therapy market. However, financial challenges and a decline in revenue remain concerns.Read More>BRTX Stock 12 Month Forecast
Average Price Target
$13.00
▲(673.81%Upside)